IM-01 PI3K GAMMA INHIBITOR FOR OVERCOMING TREATMENT RESISTANCE IN COMBINATION THERAPY OF TEMOZOLOMIDE AND ANTI-PDL1 ANTIBODY FOR GLIOBLASTOMA PATIENTS

PURPOSE: Multidisciplinary therapies including immunotherapy in glioblastoma (GBM) patients often cause long survivor, while early relapse of GBM still remains. We should find factors associated with the immunotherapy-resistance for overcoming it. We previously reported that the infiltration of PD-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishikawa, Eiichi, Miyazaki, Tsubasa, Matsuda, Masahide, Takano, Shingo, Matsumura, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213340/
http://dx.doi.org/10.1093/noajnl/vdz039.051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213340/
http://dx.doi.org/10.1093/noajnl/vdz039.051

Ejemplares similares